4.8 Article

Cartilage oligomeric matrix protein is an endogenous beta-arrestin-2-selective allosteric modulator of AT1 receptor counteracting vascular injury

Journal

CELL RESEARCH
Volume 31, Issue 7, Pages 773-790

Publisher

SPRINGERNATURE
DOI: 10.1038/s41422-020-00464-8

Keywords

-

Categories

Funding

  1. National Natural Science Foundation of China [81730010, 81921001, 81922009, 31930056, 91739116, 31701230, 91839302]
  2. National Key R&D Program of China [2019YFA0801600]

Ask authors/readers for more resources

This study reveals that the extracellular matrix protein COMP acts as an endogenous allosteric biased modulator of the AT1 receptor, inhibiting specific signaling pathways through the regulation of intracellular conformational states. COMP deficiency leads to exclusive AAA formation in response to AngII infusion, indicating a potential therapeutic target for cardiovascular diseases.
Compelling evidence has revealed that biased activation of G protein-coupled receptor (GPCR) signaling, including angiotensin II (AngII) receptor type 1 (AT1) signaling, plays pivotal roles in vascular homeostasis and injury, but whether a clinically relevant endogenous biased antagonism of AT1 signaling exists under physiological and pathophysiological conditions has not been clearly elucidated. Here, we show that an extracellular matrix protein, cartilage oligomeric matrix protein (COMP), acts as an endogenous allosteric biased modulator of the AT1 receptor and its deficiency is clinically associated with abdominal aortic aneurysm (AAA) development. COMP directly interacts with the extracellular N-terminus of the AT1 via its EGF domain and inhibits AT1-beta-arrestin-2 signaling, but not Gq or Gi signaling, in a selective manner through allosteric regulation of AT1 intracellular conformational states. COMP deficiency results in activation of AT1a-beta-arrestin-2 signaling and subsequent exclusive AAA formation in response to AngII infusion. AAAs in COMP-/- or ApoE(-/-) mice are rescued by AT1a or beta-arrestin-2 deficiency, or the application of a peptidomimetic mimicking the AT1-binding motif of COMP. Explorations of the endogenous biased antagonism of AT1 receptor or other GPCRs may reveal novel therapeutic strategies for cardiovascular diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available